| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2973a15cbfd12490443484d6e82ffcbb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2019-09-25^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_736f00a404280e17b68f1a79583ab2ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_480a5572025a2098a959226d844fae48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f805d22464d7d18d864b9b56e5440bee |
| publicationDate |
2019-11-05^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-110407941-A |
| titleOfInvention |
High-affinity antibody to CD39 and its use |
| abstract |
The present invention discloses high affinity antibodies that recognize CD39. The antibody is capable of neutralizing the ATPase activity of CD39 on CD39-expressing cells. Such antibodies can be used to treat cancer and other diseases mediated by CD39 activity. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114773473-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114773473-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023186121-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022237723-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023071821-A1 |
| priorityDate |
2019-09-25^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |